Brief: PharmAbcine Collaborates With MSD To Evaluate PMC-309 With KEYTRUDA

PharmAbcine

12/12/2022 14:19

Dec 12 (Reuters) - PharmAbcine Inc  208340.KQ :
    * PHARMABCINE ANNOUNCES COLLABORATION AGREEMENT WITH MSD TO
EVALUATE ANTI-VISTA ANTIBODY PMC-309 IN COMBINATION WITH
KEYTRUDA® (PEMBROLIZUMAB)
    * PHARMABCINE- CO TO SPONSOR PHASE I STUDY IN AUSTRALIA TO
EVALUATE SAFETY, CLINICAL EFFICACY OF COMBINATION THERAPY FOR
MULTIPLE ADVANCED SOLID TUMORS
    * PHARMABCINE- MSD WILL SUPPLY KEYTRUDA FOR PHASE I STUDY IN
AUSTRALIA OF COMBINATION THERAPY FOR MULTIPLE ADVANCED SOLID
TUMORS
    * PHARMABCINE- FURTHER DETAILS OF AGREEMENT AND CLINICAL
PROTOCOLS
WERE NOT DISCLOSED

Source text for Eikon:  ID:nPnw4zyqa 
Further company coverage:  208340.KQ 
 ((Reuters.Briefs@thomsonreuters.com;))